| Literature DB >> 12599070 |
Nigel Bourne1, Fernando J Bravo, Myriam Francotte, David I Bernstein, Martin G Myers, Moncef Slaoui, Lawrence R Stanberry.
Abstract
In two recent clinical trials, a vaccine containing herpes simplex virus (HSV) type 2 glycoprotein D (gD2) and a novel adjuvant AS04 comprising alum (Al) and 3-deactylated monophosphoryl lipid A (3-dMPL) afforded HSV-seronegative women significant protection against HSV-2 genital disease (vaccine efficacy, 73% in study 1 and 74% in study 2) and limited protection against infection (46% in study 1 and 39% in study 2). In the present report, studies in the guinea pig model investigated the protection afforded by gD2/AS04 against HSV-1 and HSV-2 genital herpes and investigated whether immunization could prevent or reduce recurrent disease in guinea pigs that developed mucosal infection. Immunization with gD2/AS04 conveyed nearly complete protection against primary disease with either virus but did not prevent mucosal infection. Guinea pigs immunized with gD2/AS04 were significantly better protected against recurrent disease than were guinea pigs immunized with a gD2/Al vaccine, which suggests that inclusion of 3-dMPL improved protection against latent infection.Entities:
Mesh：
Substances：
Year: 2003 PMID： 12599070 DOI： 10.1086/374002
Source DB: PubMed Journal: J Infect Dis ISSN： 0022-1899 Impact factor: 5.226